VEGF inhibitors are associated with posterior reversible encephalopathy syndrome (PRES) – a condition characterized by headaches, vision loss (usually homonymous hemianopia), decreased mental state and seizures, with characteristic MRI findings of vasogenic edema in the occipital and parietal areas of the brain bilaterally [21]. This evidence concerns the gene VEGFA and Posterior Leukoencephalopathy Syndrome.